• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
COVID-19 Clinical Features

Long-COVID Features and Related Clinical Factors

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • While widely reported, there have been very few studies on the features of ‘Long-COVID’, and how they related to age, sex, or severity of infection
  • Taquet et al. (PLoS Medicine, 2021) estimated the incidence and co-occurence of long-COVID features, and relationship to demographic and clinical factors

METHODS:

  • Retrospective cohort study
  • Population
    • 81 million patients, mostly in the US
    • TriNetX Analytics: Linked EHRs | Anonymized data from 59 healthcare organizations (HCOs)
  • Exposures
    • COVID-19
    • Influenza
  • Study design
    • Incidence and co-occurrence of features within 6 months and in the 3 to 6 months after COVID-19 diagnosis
    • 9 core COVID-19 features: Breathing difficulties/breathlessness | Fatigue/malaise | Chest/throat pain | Headache | Abdominal symptoms | Myalgia | Other pain | Cognitive symptoms | Anxiety/depression
    • COVID-19 patients were propensity score-matched to a cohort of patients diagnosed with influenza during the same time period for comparison
    • Incidence of atopic dermatitis was used as a negative control
  • Primary outcome
    • Incidence and co-occurrence of features of long-COVID

RESULTS:

  • COVID-19 survivors: 273,618
    • Mean (SD) age: 46.3 (19.8) years | 55.6% female
  • Individuals with long-COVID features recorded
    • During the entire 6-month period: 57%
    • During the 3-to-6-month period: 36.55%
  • Incidence of long-COVID features
    • Abnormal breathing
      • In 6-month period: 18.71%
      • In 3-to-6-month period: 7.94%
    • Fatigue/malaise
      • In 6-month period: 12.82%
      • In 3-to-6-month period: 5.87%
    • Chest/throat pain
      • In 6-month period: 12.60%
      • In 3-to-6-month period: 5.71%
    • Headache
      • In 6-month period: 8.67%
      • In 3-to-6-month period: 4.63%
    • Other pain
      • In 6-month period: 11.60%
      • In 3-to-6-month period: 7.19%
    • Abdominal symptoms
      • In 6-month period: 15.58%
      • In 3-to-6-month period: 8.29%
    • Myalgia
      • In 6-month period: 3.24%
      • In 3-to-6-month period: 1.54%
    • Cognitive symptoms
      • In 6-month period: 7.88%
      • In 3-to-6-month period: 3.95%
    • Anxiety/depression
      • In 6-month period: 22.82%
      • In 3-to-6-month period: 15.49%
  • All 9 features were more frequently reported after COVID-19 than after influenza (P<0.001)
    • Overall excess incidence: 16.60%
  • Long-COVID features also co-occurred more commonly after COVID-19 than after influenza, and formed a more interconnected network
  • Significant differences in incidence and co-occurrence were associated with sex, age, and illness severity
    • Incidence of “any” long-COVID feature ranged based on age
      • 10 to 21 years: 46.42%
      • >65 years: 61.05%
    • Females: More likely to have headaches, abdominal symptoms, and anxiety/depression
    • Males: More likely to have breathing difficulties and cognitive symptoms
    • Illness severity: Associated with more features overall

CONCLUSION:

  • Clinical features of long-COVID were reported in 57% of patients within 180 days after infection
  • These features occurred and co-occurred more frequently after COVID-19 than after influenza
  • There were different clinical profiles of long-COVID based on demographics and illness severity

Learn More – Primary Sources:

Incidence, co-occurrence, and evolution of long-COVID features: A 6-month retrospective cohort study of 273,618 survivors of COVID-19

Get Mobile-Friendly COVID-19 Research Summaries with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All COVID-19 Clinical Features Posts
Next >

Related ObG Topics:

How Long Does It Take for COVID-19 Patients to Develop Antibodies?
COVID-19: What are the Potential Long-Term Cardiovascular Consequences?
Breakthrough COVID-19 Following Vaccination: What are the Risk Factors?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

Are you an
ObG Insider?

Get specially curated clinical summaries delivered to your inbox every week for free

  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Download Your ObG App
HERE!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Already a Member of ObGFirst®?

Please log in to ObGFirst to access the 2T US Atlas

Password Trouble?

Not an ObGFirst® Member Yet?

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!
ObGFirst Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site